CCX872-B

DRUG3 trials

Sponsors

Amgen, Alan Katz, Chemocentryx

Conditions

Adenocarcinoma of the PancreasPancreas CancerPancreatic Canceralvleesklier pancreatic adenocarcinoma Pancreatic cancer

Phase 1

Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma

CompletedNCT02345408

AmgenPancreatic Cancer

Start: 2015-02-28End: 2020-05-06Updated: 2025-02-27

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

WithdrawnNCT03778879

Alan KatzAdenocarcinoma of the Pancreas, Pancreas Cancer

Start: 2019-08-01End: 2019-08-31Updated: 2019-07-19

Unknown Phase

An open-label phase 1b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma.

Active, not recruitingNL-OMON42021

Chemocentryxalvleesklier pancreatic adenocarcinoma Pancreatic cancer

Start: 2015-04-20Target: 29Updated: 2024-02-28

Related Papers

Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.

Journal of Clinical Oncology2018-02-1090 citations

Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.

Journal of Clinical Oncology2017-02-0136 citations

The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients.

Journal of Clinical Oncology2016-05-201 citations